Mode
Text Size
Log in / Sign up
N/A Completed N=2,714

Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer

Source: ClinicalTrials.gov NCT01081873 ↗
Enrolled (actual)
2,714
Serious AEs
4.5%
Results posted
Mar 2012
Primary outcomePrimary: Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit — 782; 59; 45; 28 participants

Summary

Document treatment patterns and evaluate LUCRIN / LUCRIN-TRIDEPOT® (Leuprolide) and alternative therapeutic approaches to the treatment of advanced prostate cancer during normal clinical practice and in accordance with the terms of the Belgian marketing authorization and reimbursement conditions.

Outcome Measures

OutcomeResultp-value
PRIMARY
Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit
782; 59; 45; 28; 74; 33 —
PRIMARY
Effectiveness Parameter for Screening or Recurrence of Prostate Cancer: Mean Prostate-specific Antigen (PSA) at Each Visit
62.16; 12.95; 6.23; 8.01; 8.41; 8.88 —
PRIMARY
Effectiveness Parameter: the Number of Participants With a Complete or Partial Response, Stable Disease, or Progressive Disease Following Treatment at Each Visit
525; 496; 402; 668; 347; 401 —
PRIMARY
Effectiveness Parameter for Prognosis: the Number of Participants With a Survival Prognosis of > 10 Years, 5 - 10 Years, 1 - 5 Years, 6 - 12 Months, and < 6 Months
395; 132; 100; 91; 113; 75 —
PRIMARY
Treatment Patterns for Prostate Cancer Treatments: Number of Participants at Each Visit Who Took Lucrin/Lucrin Tridepot, Luteinizing Hormone-releasing Hormone (LHRH) Agonists, Anti-androgens, or Other Drug Treatments, or Who Had Surgery or Radiotherapy.
2028; 1011; 817; 640; 969; 540 —
SECONDARY
Safety Parameter: Number of Participants Reporting Serious Adverse Events (SAEs)
121 —
SECONDARY
Epidemiological Data: Mean Weight
77.36 —
SECONDARY
Epidemiological Data: Mean Age
75.39 —
SECONDARY
Epidemiological Data: Race
59; 2154; 4 —
SECONDARY
Epidemiological Data: Tumor Staging - Among Participants With a Positive Biopsy, the Number of Participants With Adenocarcinoma Tissue or Other Tissues Recorded for the Positive Biopsy.
2269; 9; 1 —
SECONDARY
Epidemiological Data: PSA at Baseline
13.66 —
SECONDARY
Epidemiological Data: Tumor Staging (Positive or Negative) Via a Rectal Examination, Prostate Biopsy, Echograph, or Magnetic Resonance Imaging (MRI) Test.
2045; 2355; 1806; 102; 439; 9 —
SECONDARY
Epidemiological Data: the Number of Participants With Tumor Stages T0, T1, T2, T3, and T4.
30; 223; 614; 1215; 220 —
SECONDARY
Epidemiological Data: Node Staging - the Number of Participants With a Positive or Negative Computerized Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) Test
374; 1212 —
SECONDARY
Epidemiological Data: Node Staging - the Number of Participants With a N0 or N1 Stage at Baseline.
1296; 360 —
SECONDARY
Epidemiological Data: Bone Scan at Baseline
497; 1353 —
SECONDARY
Epidemiological Data: Metastasis Staging (M0 or M1) at Baseline
1373; 501 —

Eligibility Criteria

Inclusion Criteria

  • Patients with advanced prostate cancer who have been prescribed Lucrin/ Lucrin-Tri-depot or any other treatment with local reimbursement guidelines; Patients willing to consent to data being collected and provided to Abbott Laboratories.

Exclusion Criteria

  • Contraindications according to the Summary of Product Characteristics (SPC).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01081873). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search